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Abstract
Background: A great deal of sub-cellular organelle positioning, and essentially all minus-ended organelle transport,
depends on cytoplasmic dynein, but how dynein’s function is regulated is not well understood. BicD is established to play a
critical role in mediating dynein function—loss of BicD results in improperly localized nuclei, mRNA particles, and a
dispersed Golgi apparatus—however exactly what BicD’s role is remains unknown. Nonetheless, it is widely believed that
BicD may act to tether dynein to cargos. Here we use a combination of biophysical and biochemical studies to investigate
BicD’s role in lipid droplet transport during Drosophila embryogenesis.
Methodology/Principal Findings: Functional loss of BicD impairs the embryo’s ability to control the net direction of droplet
transport; the developmentally controlled reversal in transport is eliminated. We find that minimal BicD expression (near-
BicD
null) decreases the average run length of both plus and minus end directed microtubule (MT) based transport. A point
mutation affecting the BicD N-terminus has very similar effects on transport during cellularization (phase II), but in phase III
(gastrulation) motion actually appears better than in the wild-type.
Conclusions/Significance: In contrast to a simple static tethering model of BicD function, or a role only in initial dynein
recruitment to the cargo, our data uncovers a new dynamic role for BicD in actively regulating transport. Lipid droplets
move bi-directionally, and our investigations demonstrate that BicD plays a critical—and temporally changing—role in
balancing the relative contributions of plus-end and minus-end motors to control the net direction of transport. Our results
suggest that while BicD might contribute to recruitment of dynein to the cargo it is not absolutely required for such dynein
localization, and it clearly contributes to regulation, helping activation/inactivation of the motors.
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Introduction
Dynein is involved in many cellular processes, including mitosis,
nuclear migration, mRNA transport, mitochondrial transport,
golgi positioning, endosomal motion, transport of a variety of
axonal and dendritic vesicles, IF motion, and the transport of
pathogens such as herpes viruses. In many cases, it appears to play
dual roles: first, it is essential for transporting particular organelles
to specific locations, and second, once the organelles are
appropriately localized, dynein plays a role in anchoring them
there. Many of these cargos are transported along microtubules in
a bi-directional fashion, involving the activity of a plus-end motor
such as a kinesin family member and the activity of the minus-end
motion dynein.
The regulation of this bi-directional transport, or even uni-
directional dynein-based motion alone, is not well understood.
However, past work has uncovered a role for the protein BicD in
facilitating dynein function in a number of systems. In many of
these systems, loss of BicD function results in mislocalization of the
cargo. Most of these studies have not involved real-time imaging
and analysis. Therefore, it has not been clear to what extent the
loss of BicD function alters actual transport of the cargo in
question, as opposed to what extent it plays an essential role in
anchoring the cargo once it is appropriately delivered.
BicD was originally identified in Drosophila, in a mutant screen
for dominant maternal-effect proteins [1]. BicD mutant embryos
exhibited severe developmental defects including the loss of
positional information defining the anterior region of the embryo
and thereby giving rise to bicaudal embryos. It was later
established that this phenotype resulted primarily from the
aberrant localization of oskar mRNA, a posterior determinant
which inhibits the anterior factors bicoid and hunchback [2].
Further studies showed that this improper localization resulted
from altered dynein-based transport of the mRNA particles [3].
BicD has been demonstrated to be a component of dynein based
transport via genetic analysis in Drosophila [2,4,5]. In addition to
its role in mRNA transport, BicD has been established to play a
role in nuclear positioning in Drosophila [6] and in golgi positioning
in mammalian tissue culture [7,8].
Molecular studies have provided some insight into BicD’s
function. In mammals, two homologues of Bicaudal D, BICD1
and BICD2, are present [8,9]. BicD is highly conserved, albeit
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vivo as a homodimer [10,11]. Its C-terminus appears to bind to
cargos [12], while also being known to foster specific dynein/
dynactin interactions [8,13] (Fig 1B). BicD is generally classified as
having four well-defined coiled-coil regions (Fig. 1A) comprised of
multiple heptad repeats–without any other apparent motifs [11].
Overall, BicD has a flexible comma shaped structure with one
large and one small globular domain and an apparently flexible
linkage in between [10]. The large globular domain is believed to
be at the C-terminus where binding to the cargo occurs.
Mammalian BicD can directly interact with both Dynein and
Dynactin, and because a cargo linked N-terminal fragment of
BicD can tether dynein and subsequently induce dynein-based
transport [12], it is believed that BicD may link dynein to the
cargo. This is consistent with the studies of BicD’s role in Drosophila
mRNA transport, where overexpression of BicD leads to increased
association of dynein with the mRNA particles [14]. Thus, one
currently favored hypothesis is that BicD is a structural protein
required for dynein localization. Tools have not existed to
investigate the possibility that it might play important regulatory
roles as well.
Here, we investigate BicD’s function within the context of bi-
directional lipid droplet based transport. In contrast to other
systems where BicD has been studied, the particular strength of the
Figure 1. BicD structure and expression levels. A: Drosophila BicD is 782 amino acids in length. There are four heptad repeat motifs. The
location and type of various BicD alleles used in this study are indicated. Starbursts represent point mutations, Xs represent premature stop codons,
and horizontal bars represent specific domain deletions. B: A generalized map of the interacting regions of BicD. Dashed lines indicate an
approximate position based on data from mammalian BicD homologs. Regions displayed represent published data and not necessarily minimal
binding sites. C: Ovarian BicD levels in heat-shock rescued BicD
null ovaries are quite low compared to wild-type. Levels seen during repeat daily heat-
shocks (t=0), and three days post heat shock cessation (t=3) are shown in comparison to wild type. Lanes were loaded with equivalent amounts of
total lysate. D: Specifically examining ovarian BicD expression in t=3 ovaries indicates expressions levels approximately 1% of that in wild-type. This
is shown in comparison to a wild-type dilution series of lanes loaded with 1/32nd and 1/64th the amount of total protein loaded for the t=3 lane. E: A
comparison of embryonic BicD expression between heat shock rescued embryos whose mothers have been off heat shock for one versus three days.
F: The decrease in ovarian levels results in a decrease in embryonic levels: a comparison of BicD levels in embryos from OrR females (left) and BicD
null/
t=1 females (right). Lanes were loaded with equivalent amounts of total embryo lysate. Signal was detected with mixed anti-BicD (4C2, 1B11). G:
Quantitation of overall reduction of BicD in t=1 embryos relative to the wildtype. Both t=1 lanes were loaded with equivalent amounts of total
embryo lysate; OrR lanes for comparison were loaded with 1/32, 1/64, or 1/128th the relative amount of total sample loaded in the t=1 lanes. The
t=1 lanes have approximately the same signal strength as the OrR lysate diluted 1/64, suggesting that in the t=1 embryos there is approximately
1.6% of wildtype BicD levels. Signal is detected with mixed anti-BicD antibodies (4c2, 1B11).
doi:10.1371/journal.pone.0003763.g001
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spatial resolution, allowing a careful study of how loss of BicD
affects the properties of motion. Further, the possibility of
biochemical purifications of droplets means that it is possible to
investigate additional aspects of BicD’s function. Importantly,
while the droplets always move bi-directionally, they undergo
developmentally controlled changes in net transport[15]. Early in
development (nuclear division cycles 11–13) the droplets move but
with no net transport (‘‘phase I’’). Then, in early cycle 14, the
droplets move basally (net plus-end transport, ‘‘phase II’’). Finally,
in later cycle 14 there is net minus-end transport (‘‘phase III’’).
Thus, by studying changes in droplet-bound proteins at different
times during development, it is in principle possible to gain insight
into how transport is regulated[16].
We show that while BicD may help to recruit dynein to the
cargo, it is not absolutely essential for at least partial dynein
recruitment. Also, its role is more complicated than performing
this task alone: during development, the majority of BicD leaves
the droplet, but the dynein stays, and this subsequent departure of
BicD does not obviously alter dynein function. Our measurements
uncover a new role for BicD, in directly or indirectly contributing
to plus-end motor activity. Finally, analysis of an intriguing BicD
point mutation uncovers a clear ongoing temporally changing
regulatory role for BicD.
Results
Because BicD is reported to play a role in either the transport or
positioning of multiple organelles, and we have already established
that our droplets are moved by dynein [17], we were interested in
determining if BicD also played a role in lipid droplet transport.
Globally, the distribution of lipid droplets in the embryo can be
visualized using the neutral-lipid specific dye, Nile Red (Fig. 2C),
and also by transmitted light microscopy (Fig. 2A, B).
To investigate whether BicD played a role in droplet motion, we
first wanted to decrease the overall amount of embryonic BicD,
and determine whether this had any effect on droplet transport.
Because the proteins in early embryos are predominantly
maternally derived, and the complete loss of BicD is lethal, it
has not been possible to generate embryos entirely lacking in BicD.
Instead, we used a strategy based on a previously developed heat
shock rescue technique to deliver just enough wild-type BicD to
rescue otherwise BicD
null females [5]. Upon cessation of heat-
shocking, ovarian BicD levels fell quickly. Continued for one hour
per day, heat shocks of otherwise null mothers produced
significantly less ovarian BicD than did wild-type mothers
(Fig. 1C). Also, by three to four days post heat shock (t=3,4),
ovarian BicD levels appeared to be slightly less than 1/64
th wild
type levels–i.e., approximately 1% of wild type (Fig. 1D). This loss
of ovarian BicD resulted in a decrease in embryonic BicD (Fig. 1F);
BicD in t=1 embryos was approximately 1.6% that in wildtype
embros (Fig. 1G). Additionally, in the low BicD- embryos, BicD
levels continued to decrease as a function of time from heat shock:
there is an approximate 6-fold difference between BicD levels at
one day post heat shock (t=1) and three to four days post heat
shock (t=3,4) (Fig. 1E). Thus, in t=3,4 embryos, we calculate that
BicD levels are ,0.267% of wild-type, i.e. have been reduced
more than 3006.
Using this technique therefore allowed us to achieve very low–
and tunable–embryonic BicD levels. Examining the droplets in
these embryos, we discovered that the loss of BicD had a number
of effects. First, even when droplets are developmentally ‘clearing’
from the embryo’s edge (in Phase II), there were many fewer
droplets obvious in this peripheral region of the low BicD embryos
(Fig. 2K, L) as compared to wild-type (Fig. 2J, L). This could
simply reflect a redistribution of droplets to the embryo center
(where we are unable to quantify droplet distribution), or could
reflects an overall decrease of embryonic droplets present in the
embryo in this background. Second, loss of BicD severely altered
the global droplet distribution (Fig. 2A–C): droplets cleared in
phase II, but failed to re-cloud in phase III.
To further understand how this altered global distribution of
droplets came about, we considered a number of possibilities. The
first was that loss of BicD led to an altered microtubule network in
the embryos. To test this idea, we used confocal microscopy to
visualize the microtubule network in fixed intact embryos. While
the microtubules in the mutants appear slightly more disorganized,
variation between different embryos is seen in the microtubule
organization in both wild-type and mutants, and we observed no
gross defects in the microtubules (Fig. 2E). To further test the
viability of the microtubule network, we examined the distribution
of another cargo, yolk vesicles, whose distribution was previously
shown[18] to depend on intact microtubules. Their distribution
was approximately normal (Fig. 2D). Thus, we hypothesize that
the altered lipid droplet distribution was due to either altered
droplet transport, or impaired ability to anchor the droplets once
they were delivered.
BicD likely contributes to appropriate droplet transport
directly, through a role on the droplets
Past studies have shown that the N-terminal portion of
mammalian BicD can co-precipitate components of both the
dynein and dynactin complexes [8,12]. Also, BicD homologs have
been shown to directly bind dynein intermediate chain [13], the
dynamitin subunit of dynactin [8], and kinesin [19] (see also
Fig. 1B). This suggests that, for lipid droplets as well, BicD might
facilitate appropriate transport via direct interaction with the
transport machinery. To test whether BicD might play a direct
role in droplet transport, we first investigated whether BicD was
indeed present on the droplets. A first analysis involved purifying
droplets, by spinning lipids from an embryo lysate through a
simple sucrose step gradient. We saw, via western, that BicD signal
was found on the lipids spun to the surface and at or near the
pellet. However, it was not detectable in the fractions immediately
below the surface lipids (Fig. 2F). This suggested that BicD was not
simply everywhere in the gradient. Using the same antibodies for
immunoflouresence (in the whole embryo) clearly demonstrated a
general lack of BicD signal in the t=3 background as compared to
wild-type (Fig. 2H, I). In wild-type embryos strong punctae were
observed, which were predominantly lacking in the BicD-low
mutant. Some of these punctae were found close to lipid droplets
(Fig. 2G). Subsequent larger volume and higher speed lipid
purifications (used our previously developed protocol to purify
lipid droplets) confirmed BicD’s presence in the droplet fraction.
Extensive characterization of the purification protocol [20] has
established that the lipid droplet fraction does not have large
contaminants. The presence of BicD on the droplets is consistent
with a direct role in facilitating/regulating transport.
Lowered embryonic BicD levels alter individual droplet
motion.
To differentiate between an actual transport problem and
simply a problem tethering droplets once they are delivered, we
analyzed the motion of droplets with high temporal and spatial
resolution. While a global analysis suggested a role for BicD in
controlling the Phase III distribution of lipid droplets, altered
transport in Phase II could in principle contribute to phenotypes
BicD Regulates Transport
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droplet motion in both phase II and III. We initially examined
motion in Or-R embryos (wild-type, phase II, N=9 embryos,
n=305 droplets tracked; phase IIB, N=3 embryos, n=143
droplets; phase III, N=2 embryos, n=45 droplets), t=1
embryos (low BicD, phase II, N=11 embryos, n=52 droplets;
phase IIB,N=9 embryos, n=18 droplets) and t=3,4 embryos
(BicD,null, phase II, N=7 embryos, n=19 droplets; phase IIB,
N=5 embryos, n=12 droplets; phase III,N=5 embryos, n=50
droplets). Comparing wild-type motion to motion in the t=3
background, we find that loss of BicD shortened both plus-end
a n dm i n u s - e n dr u ni np h a s eI I ,b u to n l ym i n u s - e n dr u n si np h a s e
III (Fig. 3A, B). While we presume that decreased overall
embryonic BicD levels result in decreased droplet-bound BicD
levels (consistent with the disappearance of BicD puncta in the
low-BicD embryos, Fig 2), we cannot directly show this because
we cannot purify droplets from the limited number of developing
mutant embryos.
We also discovered a new intermediate phase of transport,
phase IIb, wherein there is a large up-regulation of both plus- and
minus-end directed run lengths in wild-type (Fig. 3C). Chrono-
logically, this phase of transport lasts for ,10 minutes, and
appears to coincide with the reversal of the net direction of
transport. In the t=3 (,null) embryos, this phase does not occur:
the quantitative parameters of droplet motion in phase II t=3
embryos are the same as for phase IIb t=3 embryos (t-test,
p=0.56). Thus, the presence of BicD is somehow required for the
regulatory changes involved in control of this set of changes in
droplet motion. Intriguingly, in the t=1 embryos where there is a
small yet significant residual amount of BicD (Fig. 1E), some form
Figure 2. Lowering BicD expression has a net effect on lipid droplet transport. A and B: Transmitted light images of developing BicD
null
(t=3) embryos indicate proper lipid droplet clearing in phase II (A), but an inability to recloud in phase III (B). C: Prior to Phase 3, during germband
extension, the neutral-lipid specific dye Nile Red shows a net position of lipid droplets which is very different between wild-type and BicD
null
embryos. D: During germband extension, DAPI autoflouresence of yolk vesicles does not indicate a significantly different positioning of these
cargoes. Dashed lines delineate the embryos edge. E: No gross defects are observed in the MT structure of mutant embryos, as exemplified by the
above image of MT immunoflouresence. Both images show microtubules passing from above, between, and below the syncytial nuclei. F: BicD
localizes to the layer of lipid droplets which spin up through a sucrose gradient during centrifugation from an initial embryo lysate due to their
bouyent density. Equal volumes of extracted sample were loaded per lane of the western. BicD signal can be found in the pellet, the layer
immediately above the pellet (-800), and at the surface where lipid droplets coalesce. G: Confocal analysis of whole fixed embryos shows some BicD
signal (green) close to droplets (red). Red signal represents the droplets specific marker LSD2. Lipid droplets generally average approximately 500n m
in size. H and I: With less magnification, standard fluorescence microscopy shows significant punctual staining of the cytoplasm in Phase I wild-type
embryos (H) but not in Phase I, BicD
null (t=3) embryos (I). Here, green is BicD, and red is the lipid droplet specific protein LSD2. J and K: Phase II DIC
images show a clear difference in the number of lipid droplets near the nuclei. Dashed lines specify the position of the nuclei and red arrows are
shown indicating the position of several lipid droplets. L: Automated analysis of the number of droplets observed per frame, in phase II, confirms the
apparent decrease in droplets seen at the periphery of the embryo in ‘t=1’ and ‘t=3–4’ mutant backgrounds.
doi:10.1371/journal.pone.0003763.g002
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the t=1 embryos, the plus-end run lengths go down instead of up
(Fig. 3). This is statistically obvious for plus-end runs (t-test,
p=5.3610
24; Fig. 3B), and there is a hint that this might be true
for minus-end motion as well (Fig. 3A), although we cannot be
certain because the effect in the minus-end direction is small, and
within uncertainty (t-test, p=0.12). Regardless, the decrease in
plus-end run lengths during the phase II to IIb transition of the
t=1 embryos (t-test, p,0.04), is in the opposite direction from the
change seen in wild-type where run-lengths increase (t-test,
p,0.04), suggesting that the exact levels of BicD present may
play an important role during this transition under normal
circumstances in the wild-type. Supporting the hypothesis that
plus-end transport may be quite sensitive to BicD levels, we note
that in phase II, minus-end motion in the t=1 and t=3
backgrounds is approximately the same (t-test, p=0.56; Fig. 3A),
but the small amount of additional BicD present in the t=1
embryos is enough to significantly improve Phase II plus-end
motion above that found in the t=3 embryos (t-test, p=0.049;
Fig. 3B).
Droplet-bound BicD levels are temporally changing, and
regulated
Since the t=1/t=3 experiments suggested that BicD levels may
be important, we investigated whether droplet-bound BicD levels
changed in conjunction with normal developmental changes in
droplet motion. To do this, rather than purifying droplets from
embryos in a 4-hour collection, we used a previously developed
approach [16,20] to do temporally staged purifications, enabling
us to investigate whether there were any changes in droplet-bound
BicD levels as a function of time. To our surprise, levels of BicD on
the droplet decreased precipitously from phase 1 to 3 (Fig. 4A).
This result was repeated multiple times and sample volumes per
lane were normalized for total protein each time.
Droplet-bound BicD levels could be actively controlled, or could
passively reflect changing embryonic levels of BicD. To differen-
tiate between these possibilities, we did temporally controlled
collections, as described above with respect to droplet purifica-
tions. However, rather than purifying the droplets, we simply
looked at overall embryonic levels of BicD. We found (Fig. 4B) that
embryonic BicD levels are relatively stable during this period,
Figure 3. Droplet distribution is altered due to BicD-induced changes in Droplet motion. A: BicD contributes to correct minus-end
motion. In the t=3,4 null background, minus-end directed run lengths are shorter in all three phases under consideration. While a clear run length
peak is present in phase IIb of wild-type, there is no such peak in the null. B: Comparison of plus-end directed run lengths shows that BicD affects this
direction of transport as well, although, not in phase III (B). Note the difference between t=1 and t=3 plus-end run lengths (t-test, p=0.049) in phase
II (A). A similar difference is not apparent in the minus-end direction (t-test, p=0.56) of transport (B). C and D: The net reversal of directionality seen
to occur in phase IIb for wild-type (C) does not occur in the mutant (D).
doi:10.1371/journal.pone.0003763.g003
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directly regulated.
Given the above t=1/t=3 results, and the observed changes in
BicD levels, it seems likely that regulated changes in droplet-bound
BicD levels could functionally contribute to the regulation of
droplet transport and net directionality. Past studies reported that,
when purposely attached to a cargo, an N-terminal fragment of
mammalian BicD alone could recruit dynein to a given cargo [12].
Therefore, one appealing scenario is that droplet-bound BicD
tethers dynein to the cargo, and thus droplet-bound BicD levels
directly control transport by determining the amount of cargo-
bound dynein. Then, regulating droplet-bound BicD levels could
be used to regulate droplet-bound dynein levels, and potentially
dynein activity. To investigate this possibility, we examined the
amount of dynein bound to the droplets using staged lipid droplet
purifications. DIC is hard to detect in western blots, so we have
significantly more variability than for many other proteins.
Nonetheless, we do not generally detect an obvious change in
droplet-bound dynein levels as a function of developmental stage
(Fig. 4C), suggesting there are likely not dramatic changes in the
amount of dynein bound to the droplets in different developmental
phases (though these measurements are not sensitive enough to
detect subtle changes). Additionally, wild-type minus-end run
lengths are approximately constant between phase I, II, and III
[15], although they do increase briefly in the newly discovered
phase IIb (Fig. 3C). Also, minus-end stalling forces (which reflect
the number of engaged motors) have been shown to be higher in
phase II than in phase I [15], although droplet-bound BicD is
much lower in phase II than in phase I. Since the drastic fall in
droplet BicD levels does not clearly coincide with altered minus-
end run lengths in wild-type, or in reduced minus-end stalling
forces, it seems unlikely that in phases I through III the majority of
BicD would be playing an important role in tethering dynein to
the cargos.
To test the idea that BicD may not be absolutely essential for
minus-end motility, we compared droplet motion in low (t=1) and
,null (t=3) BicD expression backgrounds. We observed minus-
end motion that was statistically similar in the low and extremely
low BicD backgrounds, despite the approximate six-fold difference
in BicD expression (Fig. 1E). This suggests that by the time we
reach t=3 BicD levels, we are observing minus-end directed
transport on droplets that are functionally null for BicD, consistent
with the idea that BicD may not be absolutely required for droplet
motion. However, if BicD is important for initial recruitment of
dynein, we might expect that the percentage of droplets moving to
be decreased. Our automated analysis found that, in phase II, the
number of moving droplets per frame was essentially the same
between the t=1 and t=3 backgrounds, but quite reduced
relative to the wild-type case (see below). These observations are
consistent with a model that there is a basal amount of dynein that
makes it to the droplets in a BicD-independent fashion, but that
some of the droplet dynein initially is recruited via BicD (during
embryogenesis), and that only droplets with dynein are able to
transport themselves into the forming embryo. However, other
interpretations are also possible (see discussion).
Mutant analysis to gain insight into BicD’s functions
Given the sudden BicD-dependent change in motion from
phase II to IIB, it is possible that BicD has two roles—an initial
structural one, possibly recruiting dynein as previously discussed
by others, and a latter dynamic regulatory role, once the dynein is
recruited. To further investigate this idea, and identify possibly
separable functions of BicD, we undertook a structure-function
study of a number of BicD mutants. We used a genetic strategy,
wherein we evaluated whether specific mutations in BicD affected
functions important for lipid droplet motion. Experimentally, our
goal was to determine which alleles were capable of rescuing an
expected reclouding defect (Fig. 5B) in embryos from female flies
expressing very low levels of BicD. The rescue background, i.e.
P{HA::BicD}/+; BicD2/BicD2, was expected to express ap-
proximately 6% wild-type levels of BicD based on previous studies
[11]. Our strategy involved making female flies, which in addition
to the low levels of BicD, had BicD alleles that could potentially
‘‘rescue’’ the global reclouding defect.
Using the female flies heterozygous for a HA-tagged BicD
transgene (a gift from the lab of Dr. Ruth Steward), we examined
several alleles comprised of small deletions and independent point
mutations for their ability to rescue. Point mutants BicD
1 (F684I)
and BicD
2 (E224K ) appeared to strongly rescue reclouding
(Fig. 5F, G). A deletion of the second heptad repeat, from the N-
terminus, rescued as well (Fig. 5D). A deletion of the third heptad
repeat rescued, albeit perhaps not fully (Fig. 5E). By far, the
clearest failure to rescue was provided by the A40V point mutant
BicD
PA66 (Fig. 5H, I). Thus, we decided to focus on a deeper
understanding of the BicD
PA66 allele. As part of this analysis, we
tracked and analyzed droplets moving in BicD
PA66 embryos in
both phase II (N=9 embryos, n=122 droplets tracked), phase IIB
(N=5 embryos, n=183 droplets tracked), and in phase III (N=8
embryos, n=236 droplets tracked).
Further studies on the BicD
PA66 allele
Since BicD levels are important for overall function, one
possibility was that the point mutation altered protein expression
or stability. To test this possibility, we first used western blot
analysis to determine BicD levels in the PA66 mutant embryos.
We found that BicD
PA66 expression levels were similar to wild-type
(Fig. 6B). Further, rescuing with two copies of BicD
PA66 instead of
one displayed a continued reclouding defect (Fig. 5I). BicD
PA66
also displays expression similar to the H2D and BicD
1 alleles
(Figs. 6C, D), both of which clearly rescue (Fig. 5D, F). Combined,
these observations suggest that lowered BicD levels could not
Figure 4. Levels of BicD on the lipid droplets decrease sharply
with time. A: Lipids purified from staged one hour collections were
probed for BicD and showed a large decrease in the amount of BicD on
the droplet from phase I to III. Each lane was loaded with an equivalent
amount of purified protein. B: During this same time, embryonic BicD
levels are approximately constant. Each lane was loaded with an
equivalent amount of total protein. C: Phase specific lipid purifications
suggest that dynein levels on the droplets are approximately constant
throughout phase I–III. Equivalent amounts of protein were loaded per
lane.
doi:10.1371/journal.pone.0003763.g004
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PA66 allele to rescue the altered
droplet distribution.
A second possibility is that BicD function is important for
appropriate arrangement of the microtubule cytoskeleton, so that
the altered droplet transport in the BicD
PA66 embryos could reflect
a generalized microtubule defect. However, this is unlikely here
because BicD
PA66 and BicD
null (t=3) embryos have nearly
identical tracking phenotypes in phase II (t-test, p.0.75 for both
directions; Fig. 6H, I), and confocal images of phase II
microtubules in BicD
null (t=3) embryos generally appeared fine
(Fig. 2E). Additionally, the short run lengths in BicD
PA66 phase II
embryos transition to long wild-type run lengths of phase IIb
within ,4 minutes, which would imply a rapidly repaired
microtubule array, which seems unlikely. Overall, it seems unlikely
that the short run lengths in phase II of BicD
PA66 and the t=3 null
are attributable to microtubule defects.
A third possibility is that the failure of the BicD
PA66 allele to
rescue motion reflects the impaired localization of BicD
PA66 to the
droplet, due to the PA66 point mutation. To investigate this
possibility, we considered a number of lines of evidence. First,
others’ structural studies have suggested that BicD typically
attaches to cargos via its C-terminal domain, but our sequencing
analysis (Fig. 6A) indicated that the location of the point mutation
is indeed as expected, in BicD’s very N-terminal domain, far from
the C-terminal cargo-attachment region. Further, the analysis
found no additional mutations (e.g.in the C-terminal portion of the
protein) that could account for altered localization. Second, early
in development (before phase II, when we analyze motion), BicD
may recruit some portion of the Dynein to the droplets. This
hypothesis is consistent with past reports, and also with the
observation that in phases II and IIb, the number of moving
droplets in BicD
null (t=3, 4) was decreased by approximately 106
as compared to wild-type (Fig. 6F). With this in mind, we looked at
the number of droplets moving in the PA66 background, and
while it was less than in wild-type, it was roughly 36to 46more
than in the null (t=3, 4) background (Fig. 6F). Since the presence
of BicD with the PA66 mutation resulted in significantly more
moving droplets than for the BicD
null, it suggests that the PA66
form of the protein still has a reasonable ability to recruit dynein to
the droplets, consistent with the hypothesis that BicD
PA66 is indeed
able to localize to the droplets (at least early in development).
Unfortunately, because they are quite few in number, we cannot
Figure 5. Examining BicD alleles for the ability to rescue the reclouding defect of a low BicD background. A–I: Alleles comprised of
domain deletions, point mutations, and premature stop codons were examined. B–C: Negative and positive controls are shown for comparison. All
alleles appeared to rescue (C–G), with the exception of the point mutation BicD
PA66 (H–I). Rescuing with two copies of BicD
PA66 displayed a continued
failure to rescue (I). E: On average, there is the suggestion that there may be only a partial rescue phenotype seen in the BicD
H3D rescue background.
Images with purple asterisks are those with a BicD-null phenotype.
doi:10.1371/journal.pone.0003763.g005
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PA66
embryos to confirm that the BicD
PA66 protein localizes to the
droplets. Further, immunolocalization studies were inconclusive
because BicD serves many roles, so we observe punctae both close-
to and away from the droplets in both wild-type and BicD
PA66
mutant embryos (not shown). However, from a functional point of
view, tracking analysis indicates that droplet motion (and hence
BicD
PA66 function) in Phase IIb is similar to wild type (Fig. 6H, I).
This suggests that, at least in phase IIb, BicD is still physically
present on the droplet. Similarly, motion continues to be good in
phase III BicD
PA66 embryos. In phase III, BicD
PA66 run lengths of
both plus and minus direction are noticeably longer than wild type
(Fig. 6H, I). Combined, these observations suggest that BicD’s
ability to possibly initially recruit dynein to the cargo is separate
from its latter ability to regulate or alter transport. Rather than
suggesting that the A40V mutation of BicD
PA66 simply alters its
localization, the data is consistent with the hypothesis that this
mutation leaves BicD’s initial ability to recruit Dynein partially
intact, but alters BicD’s function by somehow changing its ability
to later regulate motion. Such a hypothesis would be consistent
with the point mutation being localized in a portion of the protein
previously reported to interact with dynein [12].
Discussion
Past studies have found numerous roles for BicD in contributing
to distinct dynein-mediated processes, but the exact mechanism
through which BicD contributes to appropriate minus-end
transport is not yet well established. However, evidence in a
number of systems suggests that BicD may be able to play a role in
Figure 6. An analysis of the BicD
PA66 allele’s failure to rescue. A: Sequence analysis of the BicD
PA66 allele confirmed, as expected, that there
was a single point mutation resulting in a single divergence (A40V) from the wild-type amino acid sequence. Light blue regions represent exons.
Introns are represented by the intervening thin black lines. Red bars represent the two fragments upon which sequence analysis was carried out. B–
D: BicD
PA66 expression levels are similar to wild-type (B). BicD
PA66 also showed similar expression to other alleles that were capable of rescue such as
BicD
1 and BicD
H2D (C, D). Equivalent amounts of total embryo lysate were loaded per lane for each independent comparison (B–D). E: In phase II,
BicD
PA66 analysis identified a total number of droplets per frame intermediate between the wild-type and the null (‘t=1’, ‘t=3,4’) values. F: Also in
phase II, the identified number of moving droplets in the BicD
PA66 background was intermediate to the lower null values and the higher wild-type
values. G: In the embryo, both BicD
+ and BicD
PA66 appear to be phosphorylated as indicated by the resulting shift following phosphatase (C.I.P.)
treatment. H–J: Particle tracking of BicD
PA66 showed that phase II run lengths were identical to the BicD
null (t=3) for both directions of transport (t-
test, p.0.75 for both directions) while phase IIb run lengths were similar to wild-type (t-test, p.0.17) for both directions of transport (H, I). Phase III
run lengths did not come back down from the phase IIb peak as seen in wild type. BicD
PA66 displayed an inability to reverse the net direction of
transport, while also displaying a slight bias for net plus-end directed transport (J).
doi:10.1371/journal.pone.0003763.g006
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but rely heavily on over-expression studies, and/or expression of
truncated forms of the protein, and so leave open the question of
whether BicD levels or activity are changed as part of the usual
regulatory process. In addition, even accepting that BicD is
important as a dynein recruiter, there has been open the question
of whether BicD plays any continuing regulatory roles, distinct
from making sure that the transport complex is appropriately set
up. Our studies have investigated these questions within the
context of bi-directional lipid droplet motion in Drosophila
embryos.
BicD appears not to function only as a static dynein
tether
Our data is consistent with the hypothesis that BicD plays a role
in recruiting dynein to the cargo: loss of BicD function leads to
many fewer droplets present in the embryo, and hence fewer
moving droplets, consistent with a role for BicD in recruiting
dynein to droplets during embryogenesis, allowing them to be
subsequently delivered into the egg. However, some dynein
recruitment is BicD-independent, because the same number of
droplets make it into the embryo in the t=1 and t=3 embryos
(and approximately the same number of droplets are moving in
these two backgrounds) as determined from tracking analysis, in
spite of the 66difference in BicD levels, and the fact that in the
t=3 embryos BicD levels have been reduced ,3756 relative to
the wildtype, so it seems unlikely that there is still enough BicD
remaining to be functional. This finding is consistent with past
work investigating BicD’s role in mRNA transport, which also
concluded that BicD was not absolutely essential to recruit dynein
[14]. Although our favored interpretation is that BicD plays a role
in dynein recruitment, past work [21,22] suggested that in ovaries
of BicD-mutant mothers, the microtubule cytoskeleton can be
impaired, resulting in improper transport of components into the
developing embryos. Such disorganization could contribute as well
to the apparent decrease in droplets present in the BicD-mutant
embryos. Overall, although there are fewer droplets apparently
present in the mutant embryos, the percentage of droplets present
that actually move is approximately the same for all the genotypes,
at ,10%. We also note that there remains the possibility that some
of the apparent decrease in embryonic droplets reflects increased
basal droplet localization, to a central area of the embryo where
droplet quantitation is difficult.
Nonetheless, numerous lines of evidence suggest that either a
rather small portion of the available BicD tethers the dynein, or
that whatever role BicD plays in dynein recruitment occurs in a
temporally limited fashion. Loss of almost all the droplet-bound
BicD (Fig. 4A) due to normal developmental regulation does not
result in any loss of dynein from the droplets, as judged either by
western blot, or stalling forces (we’ve shown previously[23,24] that
stalling force is roughly proportional to the number of engaged
motors), or mean minus-end travel distances. A limited duration
for BicD to help assemble the motor complexes is consistent with
previous mRNA studies that suggest that the nature of the
complexes moving the mRNA particles is sensitive to BicD levels
when the complexes are formed, but not afterward [14].
BicD contributes to dynamic regulation of droplet
motion
We find that approximately the same number of droplets are
moving in both of the very low-BicD backgrounds (Fig. 6F),
although western blotting of embryos shows that there is ,66
more BicD in the t=1 background relative to the t=3
background. This suggests that at such low levels of BicD, BicD
can no longer play a significant role in recruiting dynein to the
droplets (if it could, one would expect many more moving droplets
in the t=1 embryos). Thus, we hypothesize that there is a BicD-
independent pathway for some dynein to get on to the droplets.
Assuming that this hypothesis is true, i.e. that the levels of BicD
present in both the t=1 and t=3 embryos are indeed too low to
facilitate dynein recruitment, the observation that motion is
altered between the two suggests that BicD likely has an additional
regulatory role, independent of simple dynein recruitment, and
that this regulatory role is affected by the amount of BicD present
on the cargo. The existence of this dynamic regulatory role is
further confirmed by the interesting phenotype of motion in the
PA66 background, where the mutant form of the protein allows a
dramatic change in droplet motion between phase II and IIb, but
the subsequent down-regulation of transport expected between
phase IIB and III fails to occur. A model for how the point
mutation affects BicD’s regulatory role is described below.
BicD plays a role in kinesin-mediated travel
In addition to the evidence presented above supporting roles for
regulation of minus-end transport, our data shows that loss of BicD
function leads to altered plus-end motion, suggesting a new role for
BicD: regulating plus-end transport. Our past studies suggest a
strong coupling between plus-end and minus-end motion, so one
question is whether the observed effects are indirect, and reflect a
primary role in minus-end transport, with the altered minus-end
transport resulting in plus-end transport. While we cannot be
certain, we believe it is more likely that BicD plays a role in direct
regulation of plus-end transport. First, recent work found that the
middle portion of BicD interacts with kinesin via 2-hybrid [19].
When published, the functional significance of the interaction was
unknown, but our data supports the hypothesis that it may be
important. Our recent work[24]establishes that plus-end droplet
motion is driven by kinesin-1, so it is unlikely that the effects of
BicD on plus-end motion are simply due to its effects on dynein,
although recent work suggests that this may be the case for some
mRNA transport[25]. Second, the large phase IIb run length peak
is absent in the t=3 null, consistent with the hypothesis that BicD
can acutely up-regulate both directions of transport. Third, we
noted above that plus-end transport appears to have higher dosage
sensitivity than minus-end transport to BicD levels (Fig. 3A, B).
Regardless of the exact mechanism, our studies show that BicD
plays an important role in regulating the relative contribution of
plus-end versus minus-end motion. Although run lengths are very
long in phase III of the PA66 background, a reversal of the net
direction of transport is not observed (Fig. 6J). Thus, the mutant
analysis indicates that BicD’s role in balancing plus-end versus
minus-end motion is functionally separable from its role in
facilitating overall upregulation of transport, with the resulting
long runs in each direction in Phase IIB (Fig. 6H, I).
A model for BicD function, incorporating findings from
the PA66 point mutation
BicD
PA66 is interesting in that the altered protein maintains the
ability to up-regulate the high phase IIb run lengths, yet cannot
regulate net directionality. If phase IIb run length up-regulation
requires BicD, why are run lengths in phase II of the BicD
PA66
background similar to the t=3 null? In principle, BicD could be
absent from the droplets in phase II and then rapidly accumulate
at the onset of phase IIb, but this seems unlikely given that such a
recruitment of BicD to the droplets in Phase IIB would go counter
to the continued drop in droplet-bound BicD levels which usually
occur during development.
BicD Regulates Transport
PLoS ONE | www.plosone.org 9 November 2008 | Volume 3 | Issue 11 | e3763Instead, we hypothesize that during normal wild-type develop-
ment, BicD’s motor regulatory functions can be auto-inhibited by
an intramolecular BicD-BicD interaction, but that the PA66 point
mutation has altered this interaction. Our model (Fig. 7) is as
follows. First, we hypothesize that BicD can move between two
main conformations, a ‘closed’ conformation (Fig. 7a, left) and an
‘open’ conformation (Fig 7a, right). Such a range of conformations
is consistent with past EM studies visualizing BicD [10] (however,
we do not attempt to differentiate between the possibility that
intermediate states could reflect either the modulation of time
spent in the completely-open vs completely-closed states, or the
possibility that an intermediate conformation could be adopted for
a given period of time). Secondly, it has been previously suggested
[8,12] that BicD may be capable of self-inactivation by positioning
its N- and C-terminal ends near one another. In our case, we
propose that when BicD is in its ‘closed’ state, it cannot regulate/
activate either the plus-end or minus-end motors, but that it is
maximally able to activate such motors when in an entirely ‘open’
state. This hypothesis builds on previous observations that
fragments of BicD can interact with dynein [7,8,13] and kinesin
[19], but that this ability can be absent or minimized in the full-
length protein. The functional relevance of such conformational
changes are consistent with the observation that while the N-
terminus is generally considered the dynein recruiting fragment,
there are also dynamitin (dynactin) and dynein intermediate chain
(D.I.C.) interacting regions of BicD at the C-terminal portion of
BicD (Fig 1B).
From our data studying the PA66 mutation, we further
hypothesize that the BicD-BicD inhibitory interaction is itself
actively regulated during development, and the PA66 mutation
alters the regulation of the interaction (Fig 7C). Our model is that
during wild type development, with normal BicD function, run-
lengths are in part controlled by the amount of time BicD spends
in the ‘open’ configuration–or alternatively, how ‘open’ it is
(Fig. 7B). Thus, the extremely long runs in phase IIB would reflect
BicD being completely ‘open’, and both phase II and phase III
would reflect slightly more closed forms of BicD–or alternatively,
BicD spending more time in a ‘closed’ configuration. Implicit in
this model is the hypothesis that plus-end motion is more sensitive
to exact BicD levels than minus-end motion: in phase II and III
there is a basal level of BicD activity sufficient to achieve a fixed
level of minus-end transport, but to really up-regulate minus-end
transport requires the ‘completely open’ conformation found in
IIB. In contrast, the moderately higher level of BicD activity in
phase II relative to phase III (perhaps due to higher overall levels
of the protein present on the droplet) is enough to increase plus-
end motion. Such a sensitivity of plus-end motion to exact BicD
levels/activity is consistent with the larger response of plus-end
motion to the slightly increased BicD levels in t=1 vs t=3
embryos (see Fig. 3A, B).
Interpreting the phenotype of BicD
PA66 within this general
framework suggests that the point mutation affects the regulation
of the closed versus open states of BicD, but requires that whatever
role BicD has in the initial recruitment of dynein (if any) is not
Figure 7. A proposed model for the proper regulation of BicD and the effect of the PA66 lesion. A: Past studies have indicated that BicD
has a flexible linker region between its two globular domains (Stuurman et al., 1999) and that an intramolecular interaction of the N- and C-terminal
domains might represent a closed/inactive state (A, left) that can open to interact (A, right) with other regulatory components (Hoogenraad et al.,
2001). B: Wild-type BicD may regulate its active state by either controlling how frequently it alternates between a completely open/active vs. a
completely closed/inactive state or through an ability to take an intermediate conformation. Therefore, intermediate conformations shown for wild-
type (B left, B right) are simply intended to suggest that BicD molecules are not locked in one state or the other. Yet, the open stature of BicD shown
for phase IIb of wild-type (B, middle) is intended to suggest a relatively open/active state. C: The A40V lesion of BicD
PA66 could affect N- to C-terminal
interaction within BicD. BicD
PA66 tracking results could suggest that there is an abrupt change from a closed to an open state sometime near phase
IIb, followed by a clear inability down-regulate the open/active state once it has occurred, as seen in phase III (C).
doi:10.1371/journal.pone.0003763.g007
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droplets in the BicD
PA66 embryos than in the t=1 or t=3
embryos). We hypothesize that in contrast to normal Phase II
BicD which spends some time partly open, phase II BicD
PA66 is
unable to respond to regulatory signals that keep it partly open. It
would therefore be locked completely in the ‘closed’ state, and be
unable to properly activate the motors. It thus acts as a ‘null’
mutant in phase II (i.e. the tracking phenotype is the same as for
the t=3 background). Then, for phase IIb, the mutant protein
responds appropriately to a second regulatory event, that induces
maximal opening of BicD in phase IIb. Consequently, the null
phenotype disappears, and phase IIb motion is excellent; there is
the suggestion that runs may be even longer than wild-type in the
PA66 background. Finally, just as the mutant was unable to
respond to whatever signal was present in phase II (to keep it
partly open), in phase III it is unable to respond to the signal to
partly close up, and remains fully open. Functionally, this causes
BicD
PA66 phase III run lengths to be quite similar to those of phase
IIB, i.e. the expected significant decrease in phase III run lengths
fails to occur. In conclusion, we believe that the BicD N-terminus/
C-terminus interaction is regulated to control the amount that
BicD increases plus-end and minus-end transport, and that this
regulation is altered by the A40V mutation.
Our data shows that BicD function is essential for the ability to
regulate bi-directional lipid droplet motion. BicD activity alters
both plus-end and minus-end transport, and can play a role in
balancing the relative contributions of each to allow regulated net
transport. More than simply a physical attachment between
dynein and the cargo, BicD plays interesting roles in regulating
motion. It is interesting to speculate that BicD could do this by
altering or facilitating the interaction of dynactin with dynein and
possibly kinesin. Such a hypothesis is consistent with our past work
and that of others implicating dynactin in coordinating opposite
motors [26,27], with the finding that for mRNA particles dynactin
modulates dynein-mediated movement [25], and with the previous
findings discussed above that BicD can bind both Dynactin and
Dynein, thus in principle allowing it to act as an intermediary
between the two. However, the extent that this occurs—and if so
the mechanistic details of such a process—remains for future work
to determine.
Analysis of the BicD
PA66 point mutant demonstrates that BicD’s
dual abilities—to facilitate up-regulation of transport, and to
facilitate switching the net direction of transport—are both
regulated and separable. Clearly, a great deal of future work will
be required to understand these functions at a molecular level, but
the model proposed here should be helpful in guiding some of
these new studies.
Materials and Methods
Fly Stocks and Crosses
Oregon-R was the wild-type stock. BicD
r6/Df(2L)TW119; P[w
+
hsp70 BicD]-94/+ served as our null for purposes of particle
tracking. Our BicD
r6 and Df(2L)TW119/CyO stocks were
obtained from the laboratory of Beat Suter. The associated heat
shock rescue protocol is based on that described in Swan and Suter
1996. Our slightly modified version involved one hour, once a day,
37u C heat shocks from early larval stages until adulthood. Heat
shock rescued BicD
null females and their embryos were considered
‘t=1’ one day after and ‘t=3/4’ three/four days after cessation of
the heat-shock regimen. The HA-tagged BicD transgene inserted
on the first chromosome expresses approximately 12% of wild-
type levels as previously described [11]. Therefore, a HA40::BicD/
+; BicD
null/Df female expressed approximately 6% of wild-type
BicD levels. The HA40:BicD stock, H2D stock, and H3D stock
were provided by the lab of Ruth Steward. Other stocks used in
this study are publicly available on FlyBase (http://flybase.bio.
indiana.edu). For the terminal cross resulting in embryos to be
analyzed, Wild-type OrR males were used to fertilize the females,
i.e. OrR males were crossed to (a) heat-shock rescue (null) females
(i.e. BicD
r6/Df119; Phs.BicD/+), to (b) ‘‘PA66 females’’
(HA40::BICD/+; PA66/PA66), and were also used for (c) all
reclouding rescue experiments.
Embryo Staging
Preliminary one hour embryo pre-collections were collected and
discarded in order to eliminate fertilized eggs that females flies
may have been storing. Timed phase specific purifications were
based on one hour collection windows. Phase zero collections were
stopped (e.g. lysed, fixed, etc.) immediately after collection. Phase
I, II, and III collections were aged 1.5, 2.5, and 3.5 hours
respectively following the one hour collection and then stopped. In
contrast, embryos squashed for particle tracking were staged by
eye. Phase II tracking was staged by identifying the point at which
the cellularizing plasma membrane had moved halfway down the
length of the syncytial nuclei. Phase IIb was defined as beginning
when the membrane reached the basal edge of the nuclei. Phase
III was defined as beginning at the initial dorsal movement of the
pole cells which occurs early in embryogenesis.
Isolation of Lipid Droplets by Subcellular Fractionation
Lipid droplets were purified as described previously (Cermelli et
al., 2006). In brief, embryo lysates were loaded beneath a sucrose
gradient solution and ultracentrifuged. Afterwards, the buoyant
lipid droplets were collected from the top of the gradient. Isolated
lipid droplets were then solublized in SDS-containing buffer for
subsequent SDS-PAGE analysis. The step gradient western seen in
figure 2f is based on a scaled down version of the above mentioned
purification protocol.
Particle Tracking and Statistical Analysis
Droplet motion was recorded as previously described [28].
Particle tracking was performed using automated analysis of each
video frame. Runs were defined as ending only when a reversal in
the direction of transport was observed. Pauses were included as
part of a continuous run if a reversal was not identified.
We used custom video tracking software to analyze our data
(details to be published elsewhere). Briefly, we determined the
location of lipid droplets in each video frame via template matching
[29] and then used these records of droplet positions (versus frame
number) to construct motion tracks for each particle. Because lipid
droplets are extended objects in our videos (,500 nm in diameter),
tracks could be unambiguously assembled based on particle
proximity in subsequent frames. Tracks were then filtered to identify
droplets which moved extended distances over many frames along a
line perpendicular to the edge of the embryo [16].
Here, as a quantitative measure of overall motion of droplets,
for each field of view (for all movies of a given genetic background)
we also report the ratio of the droplets moving directionally (1 um
minimum travel length) to the total number of detected droplets
(no minimum travel length requirement). This latter quantity was
determined as above, however no filtering was performed on the
tracks.
MT staining and Lipid Droplet Immunoflouresence
Microtubule staining of embryos involved dechorionating in
50% bleach, rinsing in water and fixing in a mix of heptane and
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one hour. The PBS/fixative phase was then removed and replaced
with methanol and the solution was shaken to induce devitelliniza-
tion of the embryos. These were stored overnight in methanol.
Embryos were then rehydrated in PBT (PBS+0.2% Tween) and
blocked in PBT+10% BSA. Mouse monoclonal anti-alpha-tubulin
‘AA4.3’ (DSHB) and goat-anti-mouse Alexa 488 were used to stain
microtubules. Embryos were then stored and visualized in
Vectashield mounting medium (Vector Laboratories).
Immunoflourescent labeling of lipid droplets was performed in
whole fixed embryos. Embryos were dechorionated in 50%
bleach, rinsed in water, and then fixed for 40 minutes in a 50/
50 mix of heptane and 10% Formalin solution (3.7% formalde-
hyde). Embryos were filtered out of fixative with a nylon mesh and
then hand de-vitellinized in a dish of PBS+1% BSA. BicD
immunoflouresnce was accomplished with the mouse monoclonal
anti-BicD antibody 4C2 (DSHB) at 1:500 and a goat-anti-mouse
Alexa 488 conjugated secondary antibody (Invitrogen) at 1:1000.
Lipid droplets were identified using either a 12 mg/mL Nile Red
solution or by using the lipid droplet specific rabbit polyclonal
LSD2-3b at 1:500 and a goat-anti-rabbit Alexa 568 at 1:1000 as
the secondary. All blocking and incubations were done in
PBS+10% BSA. Confocal imaging was done on a LSM 510 Meta
laser scanning microscope (Zeiss).
Sequencing of BicD
PA66
Genomic DNA was obtained from sterile PA66 homozygote
female flies by extraction, phenol/chloroform purifiction, and then
ethanol precipitation. Two PCR products were generated to
exclude the sequencing of a 7.5 kb first intron. The most 59
fragment was 400 bp and the most 39 fragment was approximately
3 kb. PCR products were then sent out for sequencing (Genewiz
DNA sequencing service).
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